Ticker

BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one…

Aclarion (NASDAQ: ACON - Get Free Report) and NeuroOne Medical Technologies (NASDAQ: NMTC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership. Institutional and Insider Ownership 7.5% of Aclarion

Aclarion (NASDAQ: ACON - Get Free Report) and InnovAge (NASDAQ: INNV - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership. Volatility and Risk Aclarion has a beta of 1.44,

Broomfield, CO, February 5, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

Company anticipates no capital raises prior to expected value enhancing catalysts  Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI)…